Royalty Pharma plc Cash And Cash Equivalents At Carrying Value

Quick Answer

Royalty Pharma plc reported Cash And Cash Equivalents At Carrying Value of $618.70 million for the year ending 2025.

  • Royalty Pharma plc showed a decrease of -33.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Royalty Pharma plc's annual report (Form 10-K), filed with the SEC on February 11, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Royalty Pharma plc's Cash And Cash Equivalents At Carrying Value has grown by 151.3%.
  • Historical annual values: Fiscal year 2025: $618.70 million | Fiscal year 2024: $929.03 million | Fiscal year 2023: $477.01 million | Fiscal year 2022: $1.71 billion | Fiscal year 2021: $1.54 billion | Fiscal year 2020: $1.01 billion | Fiscal year 2019: $246.20 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: